KRAS and non-small cell lung carcinoma: We next examined the effects of low-dose shIDO-ST treatment on immune cell infiltration in a KrasLSL-G12D/+; Trp53R270H/+(KP) mouse model of NSCLC, where Kras and p53 mutations can be activated in the lung by intranasal administration of adenovirus encoding Cre recombinase (Ad-cre) [41].